Abstract
Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.
| Original language | English |
|---|---|
| Pages (from-to) | 357-370 |
| Number of pages | 14 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2001 |
Fingerprint
Keywords
- Angiogenesis
- Chemotherapy
- Gene therapy
- Glioma
- High grade
- Nitrosoureas
- Radiotherapy
- Temozolomide
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Cite this
Changing boundaries in the treatment of malignant gliomas. / Brandes, Alba A.; Basso, Umberto; Pasetto, Lara M.
In: Expert Review of Anticancer Therapy, Vol. 1, No. 3, 2001, p. 357-370.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changing boundaries in the treatment of malignant gliomas
AU - Brandes, Alba A.
AU - Basso, Umberto
AU - Pasetto, Lara M.
PY - 2001
Y1 - 2001
N2 - Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.
AB - Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.
KW - Angiogenesis
KW - Chemotherapy
KW - Gene therapy
KW - Glioma
KW - High grade
KW - Nitrosoureas
KW - Radiotherapy
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=0035557911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035557911&partnerID=8YFLogxK
U2 - 10.1586/14787210.1.3.357
DO - 10.1586/14787210.1.3.357
M3 - Article
C2 - 12113103
AN - SCOPUS:0035557911
VL - 1
SP - 357
EP - 370
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 3
ER -